J. Brown, L. Hunt, N. Vites, C. Short, R. Gokal et al., Comparative mortality from cardiovascular disease in patients with chrome renal failure, Nephrology Dialysis Transplantation, vol.9, issue.8, pp.1136-1142, 1994.
DOI : 10.1093/ndt/9.8.1136

R. Foley, P. Parfrey, and M. Sarnak, Clinical epidemiology of cardiovascular disease in chronic renal disease, American Journal of Kidney Diseases, vol.32, issue.5, pp.112-119, 1998.
DOI : 10.1053/ajkd.1998.v32.pm9820470

P. Parfrey, Cardiac disease in dialysis patients: diagnosis, burden of disease, prognosis, risk factors and management, Nephrology Dialysis Transplantation, vol.15, issue.90005, pp.58-68, 2000.
DOI : 10.1093/ndt/15.suppl_5.58

A. Lindner, B. Charra, D. Sherrard, and B. Scribner, Accelerated Atherosclerosis in Prolonged Maintenance Hemodialysis, New England Journal of Medicine, vol.290, issue.13, pp.697-701, 1974.
DOI : 10.1056/NEJM197403282901301

. Scandinavian-simvastatin-survival-study and . Group, Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S), Lancet, vol.344, pp.1383-1389, 1994.

J. Shepherd, S. Cobbe, I. Ford, C. Isles, A. Lorimer et al., Prevention of Coronary Heart Disease with Pravastatin in Men with Hypercholesterolemia, New England Journal of Medicine, vol.333, issue.20, pp.1301-1307, 1995.
DOI : 10.1056/NEJM199511163332001

F. Sacks, M. Pfeffer, L. Moye, J. Rouleau, J. Rutherford et al., The Effect of Pravastatin on Coronary Events after Myocardial Infarction in Patients with Average Cholesterol Levels, New England Journal of Medicine, vol.335, issue.14, pp.1001-1009, 1996.
DOI : 10.1056/NEJM199610033351401

J. Downs, M. Clearfield, S. Weis, E. Whitney, D. Shapiro et al., Primary Prevention of Acute Coronary Events With Lovastatin in Men and Women With Average Cholesterol Levels, JAMA, vol.279, issue.20, pp.1615-1622, 1998.
DOI : 10.1001/jama.279.20.1615

J. Shepherd, G. Blauw, M. Murphy, E. Bollen, B. Buckley et al., Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial, The Lancet, vol.360, issue.9346, pp.1623-1630, 2002.
DOI : 10.1016/S0140-6736(02)11600-X

P. Sever, B. Dahlöf, N. Poulter, H. Wedel, G. Beevers et al., Prevention of Coronary and Stroke Events with Atorvastatin in Hypertensive Patients who have Average or Lower-than-Average Cholesterol Concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial???Lipid Lowering Arm (ASCOT-LLA), Drugs, vol.64, issue.Supplement 2, pp.1149-1158, 2003.
DOI : 10.2165/00003495-200464002-00005

U. Laufs, Beyond lipid-lowering: effects of statins on endothelial nitric oxide, European Journal of Clinical Pharmacology, vol.104, issue.11, pp.719-731, 2003.
DOI : 10.1172/JCI200114453

T. Shoji, Y. Nishizawa, T. Kawagishi, M. Tanka, K. Kawasaki et al., Atherogenic lipoprotein changes in the absence of hyperlipidemia in patients with chronic renal failure treated by hemodialysis, Atherosclerosis, vol.131, issue.2, pp.229-236, 1997.
DOI : 10.1016/S0021-9150(97)00054-3

T. Shoji, Y. Nishizawa, T. Kawagishi, K. Kawasaki, H. Taniwaki et al., Intermediate-density lipoprotein as an independent risk factor for aortic atherosclerosis in hemodialysis patients, J Am Soc Nephrol, vol.9, pp.1277-1284, 1998.

C. Baigent and M. Landry, Study of Heart and Renal Protection (SHARP), Kidney International, vol.63, pp.207-210, 2003.
DOI : 10.1046/j.1523-1755.63.s84.4.x

C. Baigent, K. Burbury, and D. Wheeler, Premature cardiovascular disease in chronic renal failure, The Lancet, vol.356, issue.9224, pp.147-152, 2000.
DOI : 10.1016/S0140-6736(00)02456-9

Y. Liu, J. Coresh, J. Eustace, J. Longenecker, B. Jaar et al., Association Between Cholesterol Level and Mortality in Dialysis Patients, JAMA, vol.291, issue.4, pp.451-459, 2004.
DOI : 10.1001/jama.291.4.451

S. Seliger, N. Weiss, D. Gillen, B. Kestenbaum, A. Ball et al., HMG-CoA reductase inhibitors are associated with reduced mortality in ESRD patients, Kidney International, vol.61, issue.1, pp.297-304, 2002.
DOI : 10.1046/j.1523-1755.2002.00109.x

C. Wanner, V. Krane, W. Marz, M. Olschewski, H. Asmus et al., Randomized Controlled Trial on the Efficacy and Safety of Atorvastatin in Patients with Type 2 Diabetes on Hemodialysis (4D Study): Demographic and Baseline Characteristics, Kidney and Blood Pressure Research, vol.27, issue.4, pp.259-266, 2004.
DOI : 10.1159/000080241

C. Wanner, Results of a randomized controlled trial with atorvastatin in dialyzed diabetic patients (4D trial), Presented at the annual meeting of the, 2004.

J. Blasetto, E. Stein, W. Brown, R. Chitra, and A. Raza, Efficacy of rosuvastatin compared with other statins at selected starting doses in hypercholesterolemic patients and in special population groups, The American Journal of Cardiology, vol.91, issue.5, pp.3-10, 2003.
DOI : 10.1016/S0002-9149(03)00003-1

M. Chapman, M. Caslake, C. Packard, and F. Mctaggart, New dimension of statin action on apoB atherogenicity, Clinical Cardiology, vol.124, issue.S1, pp.7-10, 2003.
DOI : 10.1002/clc.4960261304

H. Brewer and . Jr, benefit-risk assessment of Rosuvastatin 10 to 40 milligrams, The American Journal of Cardiology, vol.92, issue.4, pp.23-29, 2003.
DOI : 10.1016/S0002-9149(03)00779-3

D. Cox, Regression models and life tablets (with discussion), J Royal Stat Soc, vol.74, pp.187-220, 1972.

M. Austin, J. Breslow, C. Hennekens, J. Buring, W. Willett et al., Low-Density Lipoprotein Subclass Patterns and Risk of Myocardial Infarction, JAMA: The Journal of the American Medical Association, vol.260, issue.13, pp.1917-1921, 1988.
DOI : 10.1001/jama.1988.03410130125037

H. Campos, J. Genest, . Jr, E. Blijlevens, J. Mcnamara et al., Low density lipoprotein particle size and coronary artery disease, Arteriosclerosis, Thrombosis, and Vascular Biology, vol.12, issue.2, pp.187-195, 1992.
DOI : 10.1161/01.ATV.12.2.187

B. Lamarche, A. Tchernof, S. Moorjani, B. Cantin, G. Dagenais et al., Small, Dense Low-Density Lipoprotein Particles as a Predictor of the Risk of Ischemic Heart Disease in Men: Prospective Results From the Quebec Cardiovascular Study, Circulation, vol.95, issue.1, pp.69-75, 1997.
DOI : 10.1161/01.CIR.95.1.69

F. Sacks, P. Alaupovic, L. Moye, T. Cole, B. Sussex et al., VLDL, Apolipoproteins B, CIII, and E, and Risk of Recurrent Coronary Events in the Cholesterol and Recurrent Events (CARE) Trial, Circulation, vol.102, issue.16, pp.1886-1892, 2000.
DOI : 10.1161/01.CIR.102.16.1886

O. Neal, D. Lee, P. Murphy, B. Best, and J. , Low-density lipoprotein particle size distribution in end-stage renal disease treated with hemodialysis or peritoneal dialysis, American Journal of Kidney Diseases, vol.27, issue.1, pp.84-91, 1996.
DOI : 10.1016/S0272-6386(96)90034-7

M. Königer, T. Quaschning, C. Wanner, P. Schollmeyer, and A. Krämer-guth, Abnormalities in lipoprotein metabolism in hemodialysis patients, Kidney International, vol.56, pp.248-250, 1999.
DOI : 10.1046/j.1523-1755.1999.07166.x

C. Deighan, M. Caslake, M. Mcconnell, J. Boulton-jones, and C. Packard, Atherogenic lipoprotein phenotype in end-stage renal failure: Origin and extent of small dense low-density lipoprotein formation, American Journal of Kidney Diseases, vol.35, issue.5, pp.852-862, 2000.
DOI : 10.1016/S0272-6386(00)70255-1

C. Wanner and T. Quaschning, Dyslipidemia and renal disease: pathogenesis and clinical consequences, Current Opinion in Nephrology and Hypertension, vol.10, issue.2, pp.195-201, 2001.
DOI : 10.1097/00041552-200103000-00007

C. Fytili, E. Progia, S. Panagoustsos, E. Thodis, P. Passadakis et al., LIPOPROTEIN ABNORMALITIES IN HEMODIALYSIS AND CONTINUOUS AMBULATORY PERITONEAL DIALYSIS PATIENTS, Renal Failure, vol.16, issue.4, pp.623-630, 2002.
DOI : 10.1081/JDI-120013966

C. Wanner, W. Horl, C. Luley, and H. Wieland, Effects of HMG-CoA reductase inhibitors in hypercholesterolemic patients on hemodialysis, Kidney International, vol.39, issue.4, pp.754-760, 1991.
DOI : 10.1038/ki.1991.92

Y. Nishizawa, T. Shoji, M. Emoto, K. Kawasaki, T. Konishi et al., Reduction of intermediate density lipoprotein by pravastatin in hemo-and peritoneal dialysis patients, Clin Nephrol, vol.43, pp.268-277, 1995.

Y. Nishizawa, T. Shoji, T. Tabata, T. Inoue, and H. Morii, Effects of lipid-lowering drugs on intermediate-density lipoprotein in uremic patients, Kidney International, vol.56, pp.134-136, 1999.
DOI : 10.1046/j.1523-1755.1999.07133.x

O. Nishikawa, M. Mune, M. Miyano, T. Nishide, A. Maeda et al., Effect of simvastatin on the lipid profile of hemodialysis patients, Kidney International, vol.56, pp.56-219, 1999.
DOI : 10.1046/j.1523-1755.1999.07157.x

D. Saltissi, C. Morgan, R. Rogby, and J. Westhuyzen, Safety and efficacy of simvastatin in hypercholesterolemic patients undergoing chronic renal dialysis, American Journal of Kidney Diseases, vol.39, issue.2, pp.283-290, 2002.
DOI : 10.1053/ajkd.2002.30547

H. Holdaas, B. Fellström, A. Jardine, I. Holme, G. Nyberg et al., Effect of fluvastatin on cardiac outcomes in renal transplant recipients: a multicentre, randomised, placebo-controlled trial, The Lancet, vol.361, issue.9374, pp.2024-2031, 2003.
DOI : 10.1016/S0140-6736(03)13638-0

P. Jones, M. Davidson, E. Stein, H. Bays, J. Mckenney et al., Comparison of the efficacy and safety of rosuvastatin versus atorvasatatin, simvastatin, and pravastatin across doses

A. Olsson, F. Mctaggart, and A. Raza, Rosuvastatin: A Highly Effective New HMG-CoA Reductase Inhibitor, Cardiovascular Drug Reviews, vol.39, issue.Suppl B, pp.303-328, 2002.
DOI : 10.1111/j.1527-3466.2002.tb00099.x

F. Locatelli, B. Canaud, K. Eckardt, P. Stenvinkel, C. Wanner et al., Oxidative stress in end-stage renal disease: an emerging threat to patient outcome, Nephrology Dialysis Transplantation, vol.18, issue.7, pp.1272-1280, 2003.
DOI : 10.1093/ndt/gfg074

M. Annuk, M. Zilmer, L. Lind, T. Linde, and B. Fellstrom, Oxidative stress and endothelial function in chronic renal failure, J Am Soc Nephrol, vol.12, pp.2747-2752, 2001.

R. Rosenson, Statins in atherosclerosis: lipid-lowering agents with antioxidant capabilities, Atherosclerosis, vol.173, issue.1, pp.1-12, 2004.
DOI : 10.1016/S0021-9150(03)00239-9

M. Annuk, L. Lind, T. Linde, and B. Fellström, Impaired endothelium-dependent vasodilatation in renal failure in humans, Nephrology Dialysis Transplantation, vol.16, issue.2, pp.302-306, 2001.
DOI : 10.1093/ndt/16.2.302

T. Stalker, A. Lefer, and R. Scalia, A new HMG-CoA reductase inhibitor, rosuvastatin, exerts anti-inflammatory effects on the microvascular endothelium: the role of mevalonic acid, British Journal of Pharmacology, vol.57, issue.3, pp.406-412, 2001.
DOI : 10.1038/sj.bjp.0704070

R. Foley, THE CLINICAL EPIDEMIOLOGY OF CARDIOVASCULAR DISEASES IN CHRONIC KIDNEY DISEASE: Clinical Epidemiology of Cardiac Disease in Dialysis Patients: Left Ventricular Hypertrophy, Ischemic Heart Disease, and Cardiac Failure, Seminars in Dialysis, vol.10, issue.suppl 1, pp.111-117, 2003.
DOI : 10.1046/j.1525-139X.2003.160271.x

S. Su, C. Hsiao, C. Chu, B. Lee, and T. Lee, Effects of pravastatin on left ventricular mass in patients with hyperlipidemia and essential hypertension, The American Journal of Cardiology, vol.86, issue.5, pp.514-518, 2000.
DOI : 10.1016/S0002-9149(00)01004-3

J. Kjekshus, T. Pederson, A. Olsson, O. Faergeman, and L. Pyörälä, The effects of simvastatin on the incidence of heart failure in patients with coronary heart disease, Journal of Cardiac Failure, vol.3, issue.4, pp.249-254, 1997.
DOI : 10.1016/S1071-9164(97)90022-1